-+ 0.00%
-+ 0.00%
-+ 0.00%

Greenwich LifeSciences says Phase III FLAMINGO-01 data show 70%-80% recurrence reduction

PUBT·04/14/2026 10:06:36
Listen to the news
Greenwich LifeSciences says Phase III FLAMINGO-01 data show 70%-80% recurrence reduction
  • Greenwich LifeSciences disclosed preliminary open-label observations from Phase III FLAMINGO-01 evaluating GLSI-100 to prevent breast cancer recurrences.
  • Early findings in fully enrolled non-HLA-A02 arm indicated fewer recurrences following initial dosing period.
  • Immune response pattern and safety profile appeared consistent with earlier study experience.
  • Company did not outline a future presentation date for these results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.